5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study.

MLA

Chen, Li-Chi, et al. “5α-Reductase Inhibitor Exposure for Dermatologic Conditions Does Not Increase the Risk of Female Breast or Gynecologic Cancers: A Population-Based Propensity Score-Matched Cohort Study.” Journal of the American Academy of Dermatology, Oct. 2024. EBSCOhost, https://doi.org/10.1016/j.jaad.2024.10.023.

APA

Chen, L.-C., Hsieh, T. Y. J., & Senna, M. M. (2024). 5α-reductase inhibitor exposure for dermatologic conditions does not increase the risk of female breast or gynecologic cancers: A population-based propensity score-matched cohort study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.10.023

Chicago

Chen, Li-Chi, Tina Yi Jin Hsieh, and Maryanne M Senna. 2024. “5α-Reductase Inhibitor Exposure for Dermatologic Conditions Does Not Increase the Risk of Female Breast or Gynecologic Cancers: A Population-Based Propensity Score-Matched Cohort Study.” Journal of the American Academy of Dermatology, October. doi:10.1016/j.jaad.2024.10.023.